LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Genzyme’s Lemtrada (alemtuzumab), a potent, intravenous disease-modifying therapy (DMT) approved for the treatment of relapsing forms of multiple sclerosis (MS). This report series is based on primary research data collected at one month, three months, six months, and one year post-commercial availability of Lemtrada. Along with awareness and sources of familiarity, the reports assess U.S. neurologists’ trial, adoption, and use of Lemtrada, including anticipated future trends. The reports also provide information on product perceptions, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, Genzyme’s promotional efforts, and benchmarking against other previously launched MS agents.

Questions Answered:

  • Genzyme launched Lemtrada in the U.S. market as a treatment for relapsing forms of MS in December 2014. What is neurologists’ level of awareness and familiarity with Lemtrada over the course of the following year?
  •  Lemtrada enters an increasingly crowded MS market with ten branded DMT options, four of which have entered in the past five years. What are the perceived clinical advantages and disadvantages of Lemtrada compared with other marketed agents used to treat MS? How is the trial and adoption of Lemtrada tracking compared with other recent product launches in the MS market?
  • Because of its safety profile, Lemtrada’s U.S. label recommends that it should generally be reserved for later-line use in the treatment of relapsing forms of MS. Where do neurologists expect Lemtrada to fit in the MS treatment algorithm? What are the current prescribing trends among DMTs, and how do neurologists anticipate they will change over the next six months?
  •  Lemtrada is Sanofi/Genzyme’s second entrant into the MS market, following the companies’ 2012 launch of Aubagio (teriflunomide). What promotional messages and activities are Genzyme employing in support of the Lemtrada launch?


Markets covered: United States.

Primary research: 74 neurologists surveyed per report Wave; 10 qualitative interviews with a subset of survey respondents.

Indication coverage: Relapsing-remitting MS.

Table of contents

  • Lemtrada Launch Tracking Wave 2 (US)
    • Key Findings
      • Awareness and Perceptions of Lemtrada
      • Current Lemtrada Trial and Use
      • Lemtrada Positioning in the Competitive Landscape
      • Anticipated Lemtrada Trial and Use
    • Benchmarking Lemtrada Launch Success vs. MS Analogs
    • Prescriber and Nonprescriber Profiles
    • Lemtrada Awareness and Perceptions
      • Unaided and Aided Awareness of Lemtrada
        • Unaided Awareness of Drugs Currently Available for the Treatment of RR-MS
        • Aided Awareness and Level of Familiarity with Lemtrada
      • Familiarity with Lemtrada
        • Level of Familiarity with Lemtrada
        • Aided Awareness of Lemtrada Indication
        • Aided Awareness of Lemtrada Administration
        • Aided Awareness of Lemtrada Dosing Interval
      • Sources of Familiarity with Lemtrada
      • Initial Reaction to and Interest in Lemtrada
        • Initial Reaction to and Interest in Learning More About Lemtrada
        • Initial Reaction to Lemtrada
        • Interest Level in Lemtrada
      • Impressions of Lemtrada
        • Lemtrada Information Requiring Additional Education
        • Lemtrada Uniqueness and Risk-Benefit Profile Perceptions
        • Unaided Advantages and Disadvantages of Lemtrada
        • Clinical Interchangeability of Lemtrada and Other DMT Brands
        • Lemtrada Statement Agreement
      • Prescriber and Nonprescriber Profiles
        • Lemtrada: Prescriber and Nonprescriber Profile Differences
    • Lemtrada Trial and Use
      • Willingness to Prescribe Lemtrada
        • Lemtrada Trial and Willingness to Prescribe
        • Impact of Lemtrada Attributes on Willingness to Prescribe
        • Potential Issues Impacting Willingness to Prescribe Lemtrada
      • Number of Patients Currently Receiving Lemtrada
        • Lemtrada Patient Volume and Share From Clinical Trial Initiation
        • Lemtrada Discontinuation Rate and Disease Classification Allocation
        • Reasons for Starting/Switching to Lemtrada
        • Current Lemtrada Patient Origination
        • Number of DMTs Prior to Lemtrada
        • Current Lemtrada Course of Treatment
        • Severity of Infusion-Associated Reactions
        • Frequency and Prescribing Impact of Lemtrada Patient Requests
        • Follow-Up Visits and Lemtrada Treatment Response
      • Reasons for Not Yet Prescribing Lemtrada
        • Anticipated Timing for Lemtrada Prescribing Among Nonprescribers
        • Reasons for Not Yet Initiating Lemtrada Trial Among Nonprescribers
        • Reasons for Never Prescribing Lemtrada
      • Anticipated Lemtrada Use
        • Current vs. Anticipated DMT Treatment Rate in RR-MS Patients
        • Current vs. Anticipated vs. Ever Lemtrada Prescriber Base
        • Current vs. Anticipated Brand Share Among DMT-Treated RR-MS Patients
        • Lemtrada Peak Share by MS Disease Classification
        • Characteristics of Lemtrada Patient Candidates
        • Origination of Anticipated Patient Switches to Lemtrada
        • Obstacles to Prescribing More Lemtrada for RR-MS Patients
      • Lemtrada Performance on Key Attributes
        • Attribute Importance (More Important) and Lemtrada Performance
        • Attribute Importance (Less Important) and Lemtrada Performance
        • Lemtrada Performance Perception: Wave over Wave
        • Lemtrada Performance Perception: Prescriber vs. Nonprescriber
        • DMTs Most Associated with DMT Choice Attributes
        • DMTs Least Associated with DMT Choice Attributes
        • DMT Choice Attributes MOST and LEAST Associated with Lemtrada
        • Overall Satisfaction with Lemtrada Among Prescribers
    • Effectiveness of Face-to-Face Detailing for Lemtrada
      • Lemtrada Sales Representative Frequency and Reach
        • Sales Representative Detailing Reach
        • DMT Detailing Frequency Among All Surveyed Neurologists
      • Satisfaction with Lemtrada Sales Representative
        • Satisfaction Rating for Lemtrada Sales Representative Quality Attributes
        • Unaided Advice Regarding Lemtrada Promotion
      • Lemtrada Message Recall
        • Unaided Lemtrada Message Recall During Recent Detail
        • Aided Lemtrada Message Recall During Recent Detail
    • Methodology
    • Appendix
      • Primary Market Research
        • Physician Demographics
      • Additional Information
        • Likely Action Taken Following a Lemtrada Patient Request
        • Recent Changes in Management/Treatment of MS Patients
        • DMT Treatment Rate and Current Brand Share in RR-MS Patients
        • Recent DMT Prescriptions for RR-MS Patients: Treatment-Naive Patients and Switched Patients
        • Lemtrada REMS Program Participation and Ease of Enrollment
        • Perception of Lemtrada Managed Care Approval Process
        • Managed Care Requirements for Lemtrada Approval
        • Most Common DMT Failures Requested by MCOs for Lemtrada Approval
        • MCO Denial of Lemtrada Prescriptions by Patient History
        • Perceived Value of Genzyme's Support Activities for Lemtrada
        • Background, Market News, Methodology, and Objectives
      • Open-End Responses: Respondent Feedback

Author(s): John Crowley

John leads DRG’s Infectious, Niche, & Rare Diseases team and manages the market research portfolio across niche and rare diseases, anti-infectives, and vaccines. Prior to his current role, he was a Director on the team overseeing syndicated and custom work on niche and rare disease markets, as well as atopic dermatitis content in DRG’s Dermatology portfolio. He also served as a DRG analyst in the neurology space, focused mainly on the multiple sclerosis market. John holds a from the University of Massachusetts Medical School and a Bachelor’s degree from Worcester Polytechnic Institute.

Related Reports

Multiple Sclerosis | Landscape & Forecast | Disease Landscape & Forecast

The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will...

View Details

Multiple Sclerosis | Unmet Need | Detailed, Expanded Analysis - Relapsing Forms of MS (US/EU)

A growing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing forms of multiple scleros...

View Details

Multiple Sclerosis | Current Treatment | Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)

With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continue...

View Details

Multiple Sclerosis | Geographic Focus: China | Multiple Sclerosis | China In-Depth | China

MARKET OUTLOOK Multiple Sclerosis (MS), a chronic immune-mediated disease of the nervous system, is classified as a rare disease in China because of its low prevalence i...

View Details